Ropeginterferon + Azacitidine for Leukemia

This trial aims to determine the optimal dose of two drugs, ropeginterferon alfa-2b (a type of interferon therapy) and azacitidine (a chemotherapy drug), for treating leukemia with TP53 mutations, a specific genetic change related to cancer. Researchers are testing whether these drugs can effectively control the disease. Individuals recently diagnosed with MDS or AML who have the TP53 mutation and cannot undergo intensive chemotherapy might be suitable candidates for this trial. As a Phase 1 and Phase 2 trial, the research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking cancer treatment advancements.

In a previous study, ropeginterferon alfa-2b showed promise with low rates of treatment discontinuation due to side effects (8.8%) and fewer serious health issues (12.6%) compared to other treatments, suggesting it is generally well-tolerated. Another study found that ropeginterferon had fewer severe side effects than anagrelide, with only 23% of patients experiencing serious problems.

Azacitidine is used in cancer therapies. One study reported that many patients experienced severe side effects, such as a drop in white blood cells, but azacitidine remains manageable with proper medical support.

Researchers are excited about the combination of Ropeginterferon and Azacitidine for leukemia because it offers a novel approach compared to traditional chemotherapy. Unlike most standard treatments, which primarily use chemotherapy to kill rapidly dividing cells, Ropeginterferon works by boosting the immune system to specifically target cancer cells. Azacitidine, on the other hand, helps by reactivating genes that suppress tumors, potentially leading to more effective treatment outcomes. This combination aims to enhance the body's natural defenses while directly targeting the cancer, offering new hope for improved management of leukemia.

This trial will investigate the combination of ropeginterferon alfa-2b with azacitidine for treating blood cancers. Research has shown that using ropeginterferon alfa-2b with azacitidine may help treat these conditions. Ropeginterferon effectively controls blood cell levels and improves blood health. Azacitidine is already used to manage conditions like leukemia by preventing cancer cells from growing. Combining these treatments often leads to better results; studies have shown longer survival and more patients becoming disease-free compared to using azacitidine alone. Although limited information exists on how this combination works for TP53 mutations, similar treatments have shown promising results.¹⁶⁷⁸⁹